Bluejay Therapeutics

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate of functional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.

Bluejay Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $10.9B in funding across 45 round(s). With a team of 11-50 employees, Bluejay Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Bluejay Therapeutics, raised $19.2M. Discover more about their projects, partnerships, and impact on our platform.